{
    "nctId": "NCT05623397",
    "briefTitle": "A Deep Learning Method to Evaluate QT on Ribociclib",
    "officialTitle": "QT on RIBociclib measuRed by ArTificial INteliGence",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Ribociclib",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 70,
    "primaryOutcomeMeasure": "Compare the values of QTc generated by method 1 (overlap method on triplicate of 10 seconds ECG concatenated, TCM; the method of reference) versus method 2 relying on AI methodology in patients' candidate for ribociclib start",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult female patients requiring start of ribociclib based therapy for a breast cancer in their standard of care, as per their summary of product characteristic's indications\n* Association with hormone-based therapy in combination is authorized (aromatase inhibitors or fulvestrant)\n* Able to provide an informed consent\n\nExclusion Criteria:\n\n* Any allergy or contra-indication to ribociclib as mentioned in their as summary of product characteristic's\n* Patients presenting a condition precluding accurate QTc measurements on electrocardiogram, i.e paced ventricular rhythm, multiples premature ventricular or supra-ventricular contractions, ventricular tachycardia, supraventricular arrhythmia (including atrial fibrillation, flutter or junctional rhythm)\n* Patients with an atrial pacing and sinus dysfunction\n* Patients presenting a contra-indication for ECG measurement, or with a device rendering ECG measurements impossible (i.e. Diaphragmatic pacing)\n* Patients presenting a contra-indication to ribociclib start; including association with prohibited drug potentializing the risk of TdP",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}